Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies - Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common...

Senti Bio Adds Prominent Scientific and Industry Leaders to its Scientific Advisory Board - Members include world-leading experts in fields of immunotherapy drug discovery and development and commercial oncology therapeutics - - Dr. James Collins, a founder of the field of synthetic...